x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DIA-0230757
| Product Information | |
|---|---|
| CAS No. | 2428389-67-5 |
| Formula | C21H18Cl2N8O4S2 |
| Molecular Weight | 581.45 |
| Product Description | hCAI/II-IN-5 (compound MZ8) is a potent hCA I and hCA II (human carbonic anhydrase isoenzymes I and II) inhibitor, with IC50 values of 37.88 and 45.23 nM, respectively. hCAI/II-IN-5 also shows inhibition profile against α-Glycosidase and AChE, with IC50 values of 48.98 and 420.14 nM, respectively. hCAI/II-IN-5 can be used for the research of many diseases such as diabetes, Alzheimer’s disease, heart failure, ulcer, and epilepsy. |
| Format & Storage | |
|---|---|
| Format | Solid |
| Purity | > 99% |
| Shipping | Shipped on dry ice. |
| Storage | Protect from light. Powder: -80 °C, 2 years; -20 °C, 1 year. In solvent: -80 °C, 6 months; -20 °C, 1 month (protect from light). |
| Solubility Overview | Soluble in DMSO |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
